Cardiac Science (Irvine, California) has added four senior managers to its global sales and marketing team, including Kurt Lemvigh, who was named president, international operations. Mike Rice was appointed director of worldwide marketing and Ivan Bolzani was named managing director for Latin America. In addition, Kenneth Gotlib was appointed director of U.S. hospital sales. In the newly created post of president, international operations, Lemvigh assumes overall responsibility for revenue generation, new business development and management of the international distribution network and will be responsible for managing the company's operations at its Copenhagen, Denmark, facility, which is being established as Cardiac Science's international headquarters for sales and service. Lemvigh previously served as general manager of GE Medical Systems, Northern Europe, where he was responsible for the company's cardiology product line. Prior to joining Cardiac Science, Rice was vice president of marketing at Tegris, and previously was with Medtronic Physio-Control. Bolzani previously was the director of Latin America and the Caribbean operations at Medtronic Physio-Control. Gotlib has held sales management positions at several health care product companies.

Paul Williams has been named executive vice president, chief legal officer and secretary of Cardinal Health (Dublin, Ohio). He joined Cardinal Health in 1995 as assistant general counsel and was promoted to senior vice president and deputy general counsel earlier this year. Prior to joining Cardinal Health, Williams was vice president and general counsel of Information Dimensions, a computer software company.

Todd Lorenz, MD, has been named chief medical officer of Corgentech (South San Francisco, California). He joins Corgentech from Cor Therapeutics, where he served as vice president of medical affairs. Lorenz will be responsible for all of Corgentech's clinical development activities, focusing primarily on its lead product, the E2F Decoy, a combination drug and device designed to prevent vein grafts used in coronary and peripheral bypass procedures from occluding and failing. The FDA granted "fast track" designation for the E2F Decoy in March.

Eclipse Surgical Technologies (Sunnyvale, California) has promoted three senior executives to a management team, which it said, will lead the company's "transition from a manufacturing and technology orientation to a focus on worldwide sales and marketing." Richard Lanigan, head of the company's sales and marketing, was named vice president, government affairs and business development. Thomas Kinder, general manager of the company's western area, was named vice president worldwide sales. And Christopher Owens, vice president of worldwide marketing, also was named to the new senior management team. Owens recently joined Eclipse from Bausch & Lomb, where he was director of marketing for its global lamellar surgery business. The new management team will focus on the FDA-approved transmyocardial revascularization technology developed by the company, and the related percutaneous myocardial revascularization procedure. Both use the company's Eclipse lasers to drill holes in the heart muscle in order to promote blood flow to the heart for relief of angina.

Hypertension Diagnostics (St. Paul, Minnesota) has made a number of management appointments to support the commercialization of its CVProfilor DO-2020 CardioVascular Profiling System in the U.S. They include E. Paul Maloney, vice president-engineering; Frank Tappen, director of U.S. sales; Jeff Tonkinson, director of software engineering; Roxanne (Rocky) DeMarre, customer service manager; Dan Costelloe, Northwest regional sales manager; and Paul Quinn, Southwest regional sales manager. Hypertension Diagnostics makes cardiovascular profiling systems for clinical and research applications.

David Volpe has been named chief financial officer of Implant Sciences (Wakefield, Massachusetts), replacing Darlene Deptula-Hicks. Volpe has held chief financial officer positions at a number of emerging private venture backed and publicly held technology companies in the Boston area, including CardioTech International, Cynosure and EMT. Implant Sciences develops products for the medical device industry using ion implantation and thin film coatings of radioactive and non-radioactive materials.

Paul Sheils has been named president, CEO and a director of Israel-based InterCure Ltd. and its U.S. subsidiary, InterCure (Princeton, New Jersey). He succeeds Erez Gavish, co-founder of InterCure, who will become executive vice president. Prior to joining InterCure, Sheils was CEO of Medscape. He will lead global commercialization of Intercure's medical technology platform, the foundation for a series of therapeutic devices to treat several chronic conditions and diseases, including hypertension and potentially congestive heart failure, asthma and chronic obstructive pulmonary diseases. The first commercial application of the technology, RESPeRATE, is the first noninvasive, nondrug prescription device for the adjunctive treatment of hypertension. RESPeRATE recently received marketing clearance from the FDA for the adjunctive treatment of high blood pressure.

David Field has been named vice president, peripheral business, a new position with Novoste (Norcross, Georgia). Field previously was director of business development with C.R. Bard. Novoste is developing vascular brachytherapy systems for reducingin-stent restenosis.